Seres Therapeutics, Inc.

Seres Therapeutics, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Seres Therapeutics, Inc. is not a good value stock. Seres Therapeutics, Inc. is not a good growth stock. Seres Therapeutics, Inc. is not very popular among insiders. Seres Therapeutics, Inc. is a mediocre stock to choose.
Log in to see more information.
Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the d...
MCRB Fundamental Data by TradingView

News

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Globe Newswire SER-155 administration was associated with a significant reduction in both bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia...\n more…

Seres Therapeutics jumps on report of Nestle acquisition offer
Seres Therapeutics jumps on report of Nestle acquisition offer

Seeking Alpha - Healthcare Seres Therapeutics jumps on report of Nestle acquisition offer...\n more…

Seres Therapeutics strength attributed to Betaville rumor mention
Seres Therapeutics strength attributed to Betaville rumor mention

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB)
After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB)

Zacks Investment Research Seres Therapeutics (MCRB) has been on a downward spiral lately with significant selling pressure. After declining 22.5% over the past four weeks, the stock looks well positioned for a trend reversal...\n more…

Bears are Losing Control Over Seres Therapeutics (MCRB), Here's Why It's a 'Buy' Now
Bears are Losing Control Over Seres Therapeutics (MCRB), Here's Why It's a 'Buy' Now

Zacks Investment Research A downtrend has been apparent in Seres Therapeutics (MCRB) lately. While the stock has lost 32.6% over the past two weeks, it could witness a trend reversal as a hammer chart pattern was formed in...\n more…

Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript
Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript

Seeking Alpha: Transcripts Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript...\n more…